Brightgene Pharmaceutical 483, Sep 2015

Brightgene Pharmaceutical 483, Sep 2015

Peter Baker FDA$119.00

FDA investigators audited the Brightgene Pharmaceutical facility in Suzhou, China and issued inspectional observations (via FDA 483) on 10 Sep 2015.

Buy This DocumentBuy 1-Year 483 Access

Product details

  • Inspection end: 10 Sep 2015
  • Location: Suzhou, China